Relationship between COVID-19 vaccine hesitancy and willingness to pay for the booster dose of COVID-19 vaccine of oncology patients in Taizhou, China

• Published in: Annals of medicine (Helsinki) Vol. 55; no. 1; pp. 672 - 679
• Main Authors: An, Jia-Xiang, Lin, Xiao-Qing, Xie, Bo-Jian, Tung, Tao-Hsin, Zhu, Jian-Sheng
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.12.2023; Taylor & Francis Group
• Subjects: booster dose vaccine; China; COVID-19; COVID-19 Vaccines; hesitancy; Humans; Neoplasms; patients with cancer; Public Health; Vaccination; Vaccination Hesitancy; willingness to pay; China; COVID-19; booster dose vaccine; hesitancy; willingness to pay; patients with cancer
• ISSN: 0785-3890; 1365-2060; 1365-2060
• DOI: 10.1080/07853890.2023.2165705

This population-based study aimed to determine the hesitancy and willingness to pay (WTP) for the booster dose of a coronavirus disease (COVID-19) vaccine among patients with cancer in Taizhou, China. A self-administered online questionnaire was administered to patients with cancer in Taizhou, China. The chi-square test, binary logistic regression model were used to evaluate the WTP for the booster dose of a COVID-19 vaccine. The minimum sample size was 218, determined by G*Power software (latest ver. 3.1.9.7). A total of 354 patients received the survey, and 256 (72.3%) patients responded. Overall, 69.9% (179/256) of respondents were willing to pay for the booster dose, and 78.8% (141/179) of these patients were willing to pay 1-99 CNY. Furthermore, 50.4% (129/256) of respondents were hesitant to receive a COVID-19 vaccine. Being unhesitant was significantly associated with WTP for the booster dose (aOR: 3.040; 95% CI: 1.669-5.540). Hesitant patients with cancer had a lower WTP for the booster dose against COVID-19 than non-hesitant participants. These results imply that further health education programmes are essential to decrease the hesitancy of patients with cancer and enhance booster dose vaccination rates for public health improvements. KEY MESSAGES Our research showed that 70% of patients with cancer are willing to pay for the booster dose of the COVID-19 vaccine, and most are willing to pay less than 100 CNY, and this result reflects the economic value and affordability of the third dose of vaccination. COVID-19 vaccine-hesitant patients with cancer had a lower willingness to pay for a booster dose against COVID-19 than non-hesitant participants and few patients are still unwilling to pay among patients do not hesitate to receive the third dose. Therefore, promoting willingness to pay among oncology patients and addressing vaccine hesitancy remains key.